r. Thierry Conroy presented the updated results of Unicancer PRODIGE 24/CCTG PA6 trial

Five year results for PA6 trial presented at ESMO 2021

At the recent European Society For Medical Oncology (ESMO 21) Congress held September 16 -21, Dr. Thierry Conroy presented the updated results of Unicancer PRODIGE 24/CCTG PA6 trial. The five-year data from the trail has confirmed the significant benefits in all outcomes. This practice-changing research confirmed the significant improvement in the survival of pancreatic cancer patients treated with the mFOLFIRINOX chemotherapy regimen compared to the then standard treatment with gemcitabine. After surgery, two out of five patients treated with mFOLFIRINOX did not experience disease relapse compared to one out of five in those treated with gemcitabine. In addition, the survival of patients was significantly improved; about two out of three patients were alive in the mFOLFIRINOX arm versus one in two in the gemcitabine arm after three years.

More >>
 
The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer

Funding announced for clinical trial that aims to improve the outcomes for patients with colorectal cancer after surgery

The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer, has been awarded $1,426,724 from the Canadian Institutes of Health Research (CIHR) Spring Project Competition.

More >>
 
Dr. Joseph Pater receives inaugural Canadian Cancer Society Lifetime Contribution Prize

Dr. Joseph Pater receives inaugural Canadian Cancer Society Lifetime Contribution Prize

Dr. Joseph Pater, is the recipient of the Canadian Cancer Society Lifetime Contribution Prize, a new honour from the Canadian Cancer Society (CCS).

More >>
 
Dr. Elizabeth Eisenhauer by Bernard Clark

Dr. Elizabeth Eisenhauer presented with 2021 Canada Gairdner Wightman Award

Dr. Elizabeth Eisenhauer, former CCTG IND Program Director and CCTG Interim Group Director, has been presented with the 2021 Canada Gairdner Wightman Award, for her dedication to transforming the fields of cancer clinical trials and cancer drug delivery.

More >>
 

Planned trials

CLC3

Venetoclax and Obinutuzumab vs DeLayed Therapy with VEnetoclax and Obinutuzumab in Asymptomatic High-Risk Patients with CLL/SLL (EVOLVE)

EN10

Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (TAPER)

GA4

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Overexpressing Advanced Gastroesophageal Adenocarcinoma

HD11

Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma

More >>

HN11

SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)

HN12

PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)

MA41

De-Escalation of ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blOckade (DECRESCENDO)

MAC27

COMPASSHER2 Residual Disease, A Double-Blinded, Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

MAC28

De-escalation of Breast Radiation for Conservative Treatment of Stage 1, HR+, HER2 -, RS

MYC2

Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC)

More >>

Recently activated

I240

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)

More >>

I240A

A Study of Durvalumab and BA3011 in Patients with Advanced Ovarian Cancer that is Resistant to Platinum Based Chemotherapy

More >>

I240B

A Study of Durvalumab and BA3021 in Patients with Advanced Ovarian Cancer that is Resistant to Platinum Based Chemotherapy

More >>

PAC3

Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer

More >>
r. Thierry Conroy presented the updated results of Unicancer PRODIGE 24/CCTG PA6 trial

Five year results for PA6 trial presented at ESMO 2021

At the recent European Society For Medical Oncology (ESMO 21) Congress held September 16 -21, Dr. Thierry Conroy presented the updated results of Unicancer PRODIGE 24/CCTG PA6 trial. The five-year data from the trail has confirmed the significant benefits in all outcomes. This practice-changing research confirmed the significant improvement in the survival of pancreatic cancer patients treated with the mFOLFIRINOX chemotherapy regimen compared to the then standard treatment with gemcitabine. After surgery, two out of five patients treated with mFOLFIRINOX did not experience disease relapse compared to one out of five in those treated with gemcitabine. In addition, the survival of patients was significantly improved; about two out of three patients were alive in the mFOLFIRINOX arm versus one in two in the gemcitabine arm after three years.

More >>
 

Asking the right questions

Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.  

“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”

More >>
 
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 

Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.

More >>
 

Publications

Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients

Translational Lung Cancer Research 10: 826 - 838, 21 F
Fung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;

More >>

Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy

The Breast 59: 327 - 338, 2021
Partridge AH;Niman SM;Ruggeri M;Peccatori FA;Azim HA;Colleoni M;Saura C;Shimizu C;S?tersdal AB;Kroep JR;Mailliez A;Warner E;Borges VF;Amant F;Gombos A;Kataoka A;Rousset-Jablonski C;Borstnar S;Takei J;Lee JE;Walshe JM;Borrego MR;Moore HC;Saunders C;Cardoso F;Susnjar S;Bjelic-Radisic V;Smith KL;Piccart M;Korde LA;Goldhirsch A;Gelber RD;Pagani O;

More >>

Advancing Academic Cancer Clinical Trials Recruitment in Canada

Current Oncology 28: 2830 - 2839, 2021
Xu RY;Kato D;Pond GR;Sundquist S;Schoales J;Lalani S;Dancey JE;

More >>

Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial

J Am Med Assoc 325: 1277 - 1286, 2021
Meyerhardt JA;Shi Q;Fuchs CS;Meyer J;Niedzwiecki D;Zemla T;Kumthekar P;Guthrie KA;Couture F;Kuebler P;Bendell JC;Kumar P;Lewis D;Tan B;Bertagnolli M;Grothey A;Hochster HS;Goldberg RM;Venook A;Blanke C;O'Reilly EM;Shields AF;

More >>

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target

Melanoma Research 31: 27 - 37, 2021
Bao R;Surriga O;Olson DJ;Allred JB;Strand CA;Zha Y;Carll T;Labadie BW;Bastos BR;Butler M;Hogg D;Musi E;Ambrosini G;Munster P;Schwartz GK;Luke JJ;

More >>

ctDNA-based mutational landscape following anti-EGFR antibodies in metastatic colorectal cancer (mCRC) to uncover novel resistance mechanisms in the CCTG CO.26 trial

J Clin Oncol 39: 117 - 117, 2021
Topham JT;O'Callaghan CJ;Feilotter H;Kennecke HF;Lee YS;Li W;Banks K;Renouf DJ;Jonker D;Tu D;Chen EX;Loree JM;

More >>

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

European Urology 80: 275 - 279, 2021
Sweeney CJ;Martin AJ;Stockler MR;Begbie S;Chi KN;Chowdhury S;Coskinas X;Frydenberg M;Hague WE;Horvath LG;Joshua AM;Lawrence NJ;Marx GM;McCaffrey J;McDermott R;McJannett M;North SA;Parnis F;Parulekar W;Pook DW;Reaume MN;Sandhu SK;Tan A;Tan TH;Thomson A;Tu E;Vera-Badillo F;Williams SG;Yip S;Zhang AY;Zielinski RR;Davis ID;

More >>

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Nature Medicine 27: 1432 - 1441, 2021
Andrews MC;Duong CPM;Gopalakrishnan V;Iebba V;Chen WS;Derosa L;Khan MAW;Cogdill AP;White MG;Wong MC;Ferrere G;Fluckiger A;Roberti MP;Opolon P;Alou MT;Yonekura S;Roh W;Spencer CN;Curbelo IF;Vence L;Reuben A;Johnson S;Arora R;Morad G;Lastrapes M;Baruch EN;Little L;Gumbs C;Cooper ZA;Prieto PA;Wani K;Lazar AJ;Tetzlaff MT;Hudgens C;Callahan MK;Adamow M;Postow MA;Ariyan CE;Gaudreau PO;Nezi L;Raoult D;Mihalcioiu C;Elkrief A;Pezo RC;Haydu LE;Simon JM;Tawbi HA;McQuade J;Hwu P;Hwu WJ;Amaria RN;Burton EM;Woodman SE;Watowich S;Diab A;Patel SP;Glitza IC;Wong MK;Zhao L;Zhang J;Ajami NJ;Petrosino J;Jenq RR;Davies MA;Gershenwald JE;Futreal PA;Sharma P;Allison JP;Routy B;Zitvogel L;Wargo JA;

More >>